Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
List view / Grid view
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
18 August 2011 | By
Merck to pay ARIAD $25 million milestone payment for acceptance of filing...
17 August 2011 | By Pfizer
EMA accepted Pfizer’s regulatory submissions for review of two investigational compounds...
27 July 2011 | By Boehringer Ingelheim
The CHMP issued a Positive Opinion recommending the approval of Viramune® (nevirapine)...
22 July 2011 | By Takeda Pharmaceutical Company Limited
The EMA has recommended changes to the label of pioglitazone-containing medicines...
20 May 2011 | By GlaxoSmithKline
The CHMP has issued a positive opinion, recommending marketing authorisation for Benlysta® (belimumab)...
20 May 2011 | By Amgen
Amgen announced that the CHMP of the EMA has recommended a positive opinion for the marketing authorization of XGEVA™ (denosumab)...
20 May 2011 | By Merck
Merck announced that the CHMP of the EMA has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS™...
20 May 2011 | By Biogen Idec
Biogen Idec announced that FAMPYRA(R) (prolonged-release fampridine tablets) has been granted a positive opinion for conditional approval from the EMA's CHMP...